These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 12666132)

  • 21. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
    Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
    Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.
    Filella X; Blade J; Guillermo AL; Molina R; Rozman C; Ballesta AM
    Cancer Detect Prev; 1996; 20(1):52-6. PubMed ID: 8907203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma.
    Pappa C; Miyakis S; Tsirakis G; Sfiridaki A; Alegakis A; Kafousi M; Stathopoulos EN; Alexandrakis MG
    Cytokine; 2007 Feb; 37(2):171-5. PubMed ID: 17446083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone marrow microvascular density and angiogenic growth factors in multiple myeloma.
    Alexandrakis MG; Passam FJ; Ganotakis E; Dafnis E; Dambaki C; Konsolas J; Kyriakou DS; Stathopoulos E
    Clin Chem Lab Med; 2004; 42(10):1122-6. PubMed ID: 15552270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma.
    Wierzbowska A; Urbańska-Ryś H; Robak T
    Br J Haematol; 1999 May; 105(2):412-9. PubMed ID: 10233412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
    Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
    J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
    Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.
    Kaiser M; Mieth M; Liebisch P; Oberländer R; Rademacher J; Jakob C; Kleeberg L; Fleissner C; Braendle E; Peters M; Stover D; Sezer O; Heider U
    Eur J Haematol; 2008 Jun; 80(6):490-4. PubMed ID: 18331598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis.
    Shaarawy M; Zaki S; Sheiba M; El-Minawi AM
    Clin Lab; 2003; 49(11-12):625-36. PubMed ID: 14651333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Serum interleukin-6 in multiple myeloma: I. Relation to selected laboratory indicators of disease].
    Scudla V; Bacovský J; Budíková M; Klímová D; Faltýnek L
    Vnitr Lek; 1995 Sep; 41(9):593-8. PubMed ID: 7483349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humoral SPARC/osteonectin protein in plasma cell dyscrasias.
    Turk N; Kusec R; Jaksic B; Turk Z
    Ann Hematol; 2005 May; 84(5):304-10. PubMed ID: 15645230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor necrosis factor-alpha and interferon-gamma in serum of multiple myeloma patients.
    Pisa P; Stenke L; Bernell P; Hansson M; Hast R
    Anticancer Res; 1990; 10(3):817-20. PubMed ID: 2114819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feto-maternal bone remodeling in normal pregnancy and preeclampsia.
    Shaarawy M; Zaki S; Ramzi AM; Salem ME; El-Minawi AM
    J Soc Gynecol Investig; 2005 Jul; 12(5):343-8. PubMed ID: 15979546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Serum interleukin-6 in multiple myeloma. II. Relation to activity and stage of disease].
    Scudla V; Bacovský J; Budíková M; Srovnalík K; Kubalová D
    Vnitr Lek; 1995 Sep; 41(9):599-604. PubMed ID: 7483350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection.
    Chau GY; Lui WY; Chi CW; Chau YP; Li AF; Kao HL; Wu CW
    Eur J Surg Oncol; 2008 Mar; 34(3):333-8. PubMed ID: 17218078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma.
    Samani KK; Brazier M; Mathiot C; Kamel S; Jamart J; Jaubert J; Blanc M; Azaïs I; Facon T; Leleu X
    Ann Hematol; 2005 Jan; 84(1):19-24. PubMed ID: 15338198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
    Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
    Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Namba Y; Kishikawa H; Takahara S; Ichikawa Y
    Prostate Cancer Prostatic Dis; 2008; 11(3):258-63. PubMed ID: 17876341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
    Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V
    Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.